Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.

The International Diabetes Foundation (IDF) reports that more than 90 million people in China - 9.3 percent of the population - had type 2 diabetes in 2011, the most of any country. That figure is projected to grow to 129.7 million, or 12.1 percent of the population, by 2030.

India, which has 61.26 million people diagnosed with type 2 diabetes (8.3 percent of the population), ranks second only to China in total cases and third behind the United States (10.9 percent) and China in terms of prevalence. By 2030, India will have 101.2 million people with type 2 diabetes, IDF projects.

"In keeping with a long legacy of addressing global health issues through innovative and sustainable philanthropic programs, Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation are pleased to expand our philanthropic work in type 2 diabetes to China and India, where the disease has become a significant public health concern," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "We look forward to working with the Shanghai Charity Foundation to improve the management of type 2 diabetes in Shanghai."

As part of today's announcement, Together on Diabetes® awarded the Shanghai Charity Foundation (SCF) a grant of US $522,797 over three years to create an efficient and effective community-based, block-by-block approach for managing type 2 diabetes in Shanghai, a mega-city of 23 million people.

The most recent survey conducted by the Shanghai Center for Disease Control (SCDC) shows the prevalence of type 2 diabetes in Shanghai reached 16 percent last year, more than 6 percentage points above the national average and nearly 5 percentage points higher than other Chinese cities.

Working with the SCDC and the Shanghai Municipal Health Bureau, SCF will leverage existing city management systems and technology to build and pilot an integrated model of diabetes prevention and management that can be deployed in other Chinese cities.

"As their populations grow older and more sedentary, health authorities in China and India are seeing many of the same problems experienced by their Western counterparts, namely obesity and type 2 diabetes," said John Damonti, president, Bristol-Myers Squibb Foundation and vice president, Corporate Philanthropy, Bristol-Myers Squibb. "What's worse, we are seeing only the tip of the iceberg. For every patient in China or India who has been diagnosed with type 2 diabetes, there are several others who are undiagnosed or considered pre-diabetic. That is why Bristol-Myers Squibb and its Foundation are introducing to China and India the Together on Diabetes® model developed in the United States and working with prestigious partners in both countries to address this growing public health issue."

The additional $15 million commitment for Together on Diabetes® builds upon more than a decade of work by the Foundation and its partners in China to reduce health disparities and fight serious diseases by strengthening community-based health care worker capacity and integrating medical care and community-based supportive services. The first Together on Diabetes® grants in India and additional grants in China will be announced later.

Bristol-Myers Squibb is celebrating three milestones in 2012: the 125th anniversary of the company's founding; the 30th anniversary of the establishment of the company's joint venture in China, Sino-American Shanghai Squibb Pharmaceuticals Ltd.; and the 10th anniversary of the Foundation's Delivering Hope® initiative to address hepatitis B and C in Asia.

Delivering Hope® has donated more than US $4.5 million to 16 projects on mainland China and three in Taiwan. More than 8 million people in China who are at high risk of hepatitis infection have benefitted from Delivering Hope® programs over the past decade.

About Together on Diabetes®
Together on Diabetes® is a 5 year, $115 million philanthropic initiative of the Bristol-Myers Squibb Foundation to improve health outcomes of people living with type 2 diabetes in the United States, China and India by strengthening patient self-management education, community-based supportive services and broad-based community mobilization. Consistent with the Bristol-Myers Squibb Foundation's mission to reduce health disparities, the initiative targets populations disproportionately affected by type 2 diabetes.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes for patients around the world who are disproportionately affected by serious disease.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]